A/HRC/RES/41/10 associated with high prices, which impede progress towards achieving universal health coverage for all, Recalling the Declaration on Primary Health Care, adopted in October 2018 in Astana, which recognizes the need to address the inefficiencies and inequities that expose people to financial hardship resulting from their use of health-care services by ensuring better allocation of resources for health, adequate financing of primary health care, and to work towards the financial sustainability, efficiency and resilience of national health systems, appropriately allocating resources to primary health care based on the national context, Noting with concern that, for millions of people throughout the world, the full and equal enjoyment of the right to the highest attainable standard of physical and mental health remains a distant goal, Concerned about the interrelatedness between poverty and other social and economic determinants of health and the realization of the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, in particular the fact that ill health can be both a cause and a consequence of poverty, Recognizing that universal health coverage implies that all people have access without discrimination to nationally determined sets of needed promotive, preventive, curative, palliative and rehabilitative essential health-care services, and essential, safe, affordable, effective and quality medicines and vaccines, while ensuring that the use of these services does not expose users to financial hardship, with special emphasis on the poor, vulnerable and marginalized segments of the population, Welcoming General Assembly resolution 72/139 of 12 December 2017, in which the Assembly decided to convene the upcoming high-level meeting on universal health coverage, and resolution 73/131 of 13 December 2018, in which the Assembly defined its scope, modalities, format and organization, Recognizing the need for States, in cooperation with international organizations and civil society, including non-governmental organizations, philanthropic foundations, academic and research institutions and the private sector, involved at all stages of the pharmaceuticals value chain, including research and development, manufacture, distribution and supply of pharmaceutical products, to create favourable conditions at the national, regional and international levels to ensure the full and effective enjoyment of the right of everyone to the highest attainable standard of physical and mental health, Recalling that the Doha Ministerial Declaration on the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) and Public Health confirms that the Agreement does not and should not prevent members of the World Trade Organization from taking measures to protect public health, and that the Declaration, accordingly, while reiterating the commitment to the Agreement, affirms that it can and should be interpreted and implemented in a manner supportive of the rights of members of the Organization to protect public health and, in particular, to promote access to medicines for all, and further recognizes, in this connection, the right of members of the Organization to use to the full the provisions of the above-mentioned Agreement, which provide flexibility for this purpose, Welcoming the entry into force of the protocol amending the TRIPS Agreement, which adapts the rules of the global trading system to the public health needs of people in poor countries, thus contributing to the realization of the right to the enjoyment of the highest attainable standard of physical and mental health, particularly regarding poorer populations, Regretting the high number of people still without access to affordable, safe, effective and quality medicines and vaccines, and underscoring that improving such access could save millions of lives every year, and noting with deep concern that, globally, two billion people have no access to the medicines they need, while recognizing that the lack of access to medicines and vaccines is a challenge that affects people not only in developing countries but also in developed countries, even though the disease burden is disproportionately high in developing countries, 3